NASDAQ$SCPH
scPharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
scPharmaceuticals reported first quarter 2024 financial results and provided a business update.
scPharmaceuticals generated $6.1 million in net FUROSCIX revenue for Q1 2024, despite an estimated 10% impact from the Change Healthcare cyberattack. The company ended the quarter with $58.4 million in cash and cash equivalents.
- Generated net FUROSCIX revenue of $6.1 million, despite an estimated 10% negative impact to doses filled during the first quarter resulting from the Change Healthcare cyberattack as well as seasonality resulting from patient copays resetting.
- Total FUROSCIX doses written were 17,376, up 28% sequentially as compared to 13,542 in the fourth quarter of 2023.
- FUROSCIX doses filled were 8,074, up 15% sequentially from 7,016 in the fourth quarter of 2023.
- Ended the first quarter of 2024 with cash and cash equivalents of $58.4 million.
Headline financials
Revenue & EPS history
scPharmaceuticals · Revenue · Quarterly
$6.1M
Revenue by segment
scPharmaceuticals · $3.8M total across 1 segment · Q3 2023
- FUROSCIX$3.8M—100.0%
Forward guidance
scPharmaceuticals anticipates that the GTN discount will increase over time, possibly approaching 30-35% by the end of this year, consistent with prior long-term guidance. The company plans to file a sNDA by the end of this year for a low volume auto-injector for FUROSCIX, if successful.
Tailwinds
- Continued sales momentum in the first quarter.
- Leading indicators suggest treating providers are increasingly more comfortable prescribing FUROSCIX.
- Progress in contracting efforts with payers.
- Advancing life cycle and long-term growth initiatives for FUROSCIX.
- Potential expansion of the FUROSCIX indication to include NYHA Class IV heart failure patients.
Headwinds
- Seasonality resulting from patient copays resetting with the new year.
- Estimated 10% negative impact to doses filled during the quarter as a result of the Change Healthcare cyberattack.
- GTN discount is expected to increase over time.
- Dependence on the commercial success of FUROSCIX.
- Risks related to the receipt of regulatory approval for product candidates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q1 2024
+3.8%
Avg return
Earnings day
+5.8%
Avg return
5 days after
+7.1%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+52.7%
Q4 2019
Best reaction
-14.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | -7.4% | -4.6% | +11.6% | |
| Q1 2025 | +27.4% | +45.1% | +74.8% | |
| Q4 2024 | -1.0% | -1.3% | -15.5% | |
| Q3 2024 | -14.5% | -14.8% | -18.6% | |
| Q2 2024 | +2.6% | +3.7% | +11.8% | |
| Q1 2024 | +5.1% | +10.6% | -6.9% | |
| Q4 2023 | -1.1% | +2.2% | -7.8% | |
| Q3 2023 | -8.4% | — | — | |
| Q2 2023 | +0.0% | — | — | |
| Q1 2023 | -0.6% | — | — | |
| Q4 2022 | +25.0% | — | — | |
| Q3 2022 | +7.3% | — | — | |
| Q2 2022 | +8.6% | — | — | |
| Q1 2022 | +7.7% | — | — | |
| Q4 2021 | +7.0% | — | — | |
| Q3 2021 | -10.1% | — | — | |
| Q2 2021 | +4.9% | — | — | |
| Q1 2021 | -5.3% | — | — | |
| Q4 2020 | -6.6% | — | — | |
| Q3 2020 | +2.0% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | -4.0% | — | — | |
| Q4 2019 | +52.7% | — | — | |
| Q3 2019 | -5.4% | — | — | |
| Q2 2019 | +10.1% | — | — | |
| Q1 2019 | +0.6% | — | — | |
| Q4 2018 | -4.8% | — | — | |
| Q3 2018 | +1.2% | — | — | |
| Q2 2018 | +2.9% | — | — | |
| Q1 2018 | +29.2% | — | — | |
| Q4 2017 | -6.7% | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro